Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
31 Agosto 2022 - 6:30AM
Business Wire
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company
focused on the discovery and development of next-generation
synthetically lethal therapies for cancer, today announced that its
President and Chief Executive Officer, Markus Renschler, MD, will
participate in a fireside chat at the Morgan Stanley 20th Annual
Global Healthcare Conference on September 14, 2022.
Morgan Stanley 20th Annual Global Healthcare Conference Date:
Wednesday, September 14 Time: 8:35 AM EDT
A live webcast will be available in the Investors & Media
section of the Cyteir website at www.cyteir.com. A webcast replay
will also be available on the website shortly after conclusion of
the event for 30 days.
About Cyteir Therapeutics, Inc.
Cyteir is a clinical-stage oncology company that is focused on
the discovery and development of next-generation synthetically
lethal therapies to treat cancer. At Cyteir, we employ an
integrated target discovery approach that incorporates a critical
evaluation of the target biology with internal and external
information from a variety of genetic and chemical synthetic
lethality screens to fuel our drug discovery and development
pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a
selective oral investigational drug currently in a Phase 1/2
clinical trial for hematologic malignancies and solid tumors.
Follow Cyteir on social media: LinkedIn and Twitter and at
www.cyteir.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220831005133/en/
Lisa Hayes Vice President, Investor Relations and Corporate
Communications 908-868-8926 Lisa.Hayes@cyteir.com
Cyteir Therapeutics (NASDAQ:CYT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Cyteir Therapeutics (NASDAQ:CYT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024